Maravai Lifesciences Holdings (MRVI) Return on Invested Capital (2021 - 2026)

Maravai Lifesciences Holdings' Return on Invested Capital history runs 6 years deep, the most recent figure standing at 0.03% for Q1 2026.

• On a quarterly basis, Return on Invested Capital rose 2.0% year-over-year to 0.03% in Q1 2026; TTM through Mar 2026 was 0.03%, a 2.0% increase from a year earlier, with the FY2025 full-year figure at 0.07%, up 1.0% from the prior year.
• Return on Invested Capital grew to 0.03% in Q1 2026 per MRVI's latest filing, from 0.04% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.09% in Q1 2022 and bottomed at 0.07% in Q2 2025.
• The 5-year median for Return on Invested Capital is 0.0% (2024), against an average of 0.01%.
• Across the five-year window, Return on Invested Capital tumbled 62 bps in 2022 and climbed 2 bps in 2026, its largest moves.
• Year by year, Return on Invested Capital stood at 0.05% in 2022, then tumbled by 99 bps to 0.0% in 2023, then slumped by 6989 bps to 0.05% in 2024, then rose by 8 bps to 0.04% in 2025, then rose by 22 bps to 0.03% in 2026.
• Per Business Quant, the three latest MRVI Return on Invested Capital figures stand at 0.03% (Q1 2026), 0.04% (Q4 2025), and 0.04% (Q3 2025).